الرسائل الموجهة للمختصين الصحيين

XELJANZ (tofacitinib): increased risk of venous thrombo-embolism and increased risk of serious and fatal infections

Update on instruction for the preparation of Curam® (Amoxicillin Clavulanic Acid POS - powder for Oral Suspension) bottles

Ecalta 100mg Powder for Concentrate for Solution for Infusion (Anidulafungin): Solution for Infusion must no longer be frozen

Hydrochlorothiazide - Risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)

Restrictions on use; pregnancy prevention programme to be put in place.

Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).

Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation

Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI)

FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception

Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron)